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Effects of High Intakes of Fructose and Galactose, with or
without Added Fructooligosaccharides, on Metabolic
Factors, Inflammation, and Gut Integrity in a Rat Model
Nor Adila Mhd Omar,* Jan Frank, Johanita Kruger, Federica Dal Bello, Claudio Medana,
Massimo Collino, Galia Zamaratskaia, Karl Michaelsson, Alicja Wolk, and Rikard Landberg
Scope: A high fructose and galactose intake show adverse metabolic effects
in animal models and in humans, but it is yet unknown if addition of
fermentable dietary fiber can mitigate such effects. This study investigate the
effects of high intakes of fructose and galactose, with/without added
fructooligosaccharides (FOS), on metabolic factors, inflammation, and gut
integrity markers in rats.
Methods and Results: Rats (n = 6/group) receive different carbohydrates at
isocaloric conditions for 12 weeks as follows: 1) starch (control), 2) fructose,
3) galactose, 4) starch + FOS (FOS control), 5) fructose + FOS, and 6)
galactose + FOS, together with a high amount of n-6 polyunsaturated fatty
acids (n-6 PUFA) in all diets except for in 7) starch + olive oil (negative
control). The rats fed the galactose and galactose + FOS diets exhibit lower
body weight than other groups. High-galactose diets has more pronounced
effects on metabolic factors and gut permeability than high-fructose diets.
High-fructose diets show less pronounced effect on these selected markers.
No differences in inflammatory markers are detected for any of the diets.
Conclusions: The results suggest potential adverse effects of high galactose
and fructose on metabolic factors and gut integrity markers, but not on
inflammation. However, several mechanisms are at play, and general net
effects are difficult to determine conclusively for the conditions tested.
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1. Introduction
Global intake of sugar from foods
and beverages has increased in recent
decades,[1,2] accompanied by increased
incidence of obesity, diabetes, and car-
diovascular disease (CVD).[3] Sugars
represent a direct source of energy and
high intake of sugar can cause negative
effects on health. Numerous studies have
shown that large amounts of dietary sug-
ars are associated with risk factors of car-
diometabolic disease, including weight
gain, dyslipidemia, glucose intolerance,
insulin resistance, and hypertension.[4,5]
The term “sugars” refers to monosac-
charides and disaccharides. Among the
monosaccharides, glucose and fructose
are the most common, and are found
in fruits and vegetables.[6] Galactose is
mainly found in milk and other dairy
products but can also be found in veg-
etables and fruits such as celery and
cherries.[7] Sucrose, lactose, and mal-
tose are the most common disaccharides
found inmost foods.[8] Glucose, fructose,
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and galactose are mainly consumed in the form of sucrose (table
sugar), high-fructose corn syrup, and lactose.[8] Intake of sugars
from fruits is an unavoidable part of a healthy diet, but added
sugars can make the diet unhealthy. There is currently no clearly
defined threshold at which sugar intake exerts negative health
effects in humans.[9]
Both human and animal studies have shown adverse effects
of high fructose intake and increased risk of development of
metabolic syndrome, type 2 diabetes, and CVD.[10,11] High fruc-
tose intake leads to impairment of glucose tolerance, reduced in-
sulin sensitivity, hypertriglyceridemia, and hypertension in ani-
mal models.[3,12] High fructose intake may also result in stimu-
lation of hepatic de novo lipogenesis, which plays a significant
role in the development of non-alcoholic fatty liver disease.[13,14]
Moreover, there is evidence that high intake of fructose in-
creases inflammation through activation of the nuclear factor-𝜅B
(NF-𝜅B) signaling pathway and production of pro-inflammatory
cytokines, including tumor necrosis factor-alpha (TNF-𝛼) and
interleukin-6 (IL-6).[15,16]
Galactose ingested in high amounts or low galactose degra-
dation capacity is known to cause galactosemia, resulting in ox-
idative stress and cognitive and motor impairment.[17,18] In ani-
mal research, galactose-induced mimetic aging is an established
aging model. Fructose and galactose are both reducing sugars
and therefore react with amino groups, which leads to enhanced
production and accumulation of advanced glycation end prod-
ucts (AGEs) and reactive oxygen species.[19,20] Such compounds
contribute to pathological processes of age-related diseases,
such as diabetes, atherosclerosis, and neurodegeneration.[21,22]
Human studies have consistently demonstrated that AGEs
can increase oxidative stress, impair endothelial function, and
trigger inflammatory responses through activation of NF-kB,
which up-regulates TNF-𝛼, IL-6, and interleukin-1𝛽 (IL-1𝛽)
expression.[23,24]
On the other hand, intake of complex carbohydrates, such
as fructooligosaccharides (FOS), a fermentable dietary fiber, has
been associated with improved glycemic control and reduced
risk of chronic diseases, such as obesity, diabetes mellitus, and
CVD.[25,26] Gut fermentation of FOS results in production of
short-chain fatty acids (SCFA), including acetate, propionate, and
butyrate.[27] Beneficial effects of SCFA on health parameters in-
clude reduced inflammation and enhanced function of immune
cells and the intestinal barrier.[28] AWestern-type diet rich in sug-
ars and low in dietary fiber has been shown to lead to negative
metabolic effects and increased low-grade systemic inflamma-
tion as a result of impaired gut barrier integrity.[29]
In the present study, we tested the hypothesis that intake of
simple sugars, such as fructose and galactose, in high amounts
has pro-inflammatory and adverse metabolic effects, whereas
a similar diet with added FOS, which stimulates extensive fer-
mentation in the gut, could mitigate these adverse effects when
administered as part of a diet with similar macronutrient pro-
file. A high dose of sugars (50%), which has been shown to af-
fect metabolic factors and inflammation in previous studies, was
used [30–32] along with a high concentration of n-6 polyunsatu-
rated fatty acids (n-6 PUFA) as part of fat in the diet, to trigger in-
flammation. We investigated the impact of high-sugar diets with
and without additional FOS, on metabolism and low-grade sys-
temic inflammation, through assessment of metabolic factors,
inflammatory biomarkers, and gut barrier function in a 12 week
intervention study performed on rats.
2. Experimental Section
2.1. Animals and Diets
The intervention study was performed at the Institute of Nutri-
tional Sciences, University of Hohenheim, Germany. All animal
procedures were carried out in accordance with the Federation
of European Laboratory Animal Science Association (FELASA)
guidelines for care and use of laboratory animals, and were ap-
proved by the Regional Council Stuttgart (Baden-Württemberg,
Germany; trial no. V 351-18 BC).
Healthy male Sprague-Dawley rats (n = 90) were purchased
at 7 weeks of age from Janvier Labs and had initial body weight
(BW) of 250–274 g. The rats were randomly divided into seven
groups of 12 animals and one baseline control group of six an-
imals, and their metabolic status was assessed at the beginning
of the experiment. Each experimental group was provided with
different carbohydrates at isocaloric conditions as follows: 1)
starch (control) (61.5 g/100 g), 2) fructose (50 g/100 g), 3) galac-
tose (50 g/100 g), 4) starch + FOS (FOS control) (starch: 54
g/100 g, FOS: 15 g/100 g), 5) fructose + FOS (fructose: 50 g/100
g, FOS: 15 g/100 g) and 6) galactose + FOS (galactose: 50 g/100
g, FOS: 15 g/100 g), all together with a high amount of n-6 PUFA
from safflower oil (6 g/100 g) (Sigma Aldrich), and 7) starch +
olive, a negative control group that received the starch diet but
with the n-6 component supplied as olive oil (Table 1). No infor-
mation was found about the exact n-6 PUFA amounts in the olive
oil provided. However, many studies have reported that olive oil
contains low amounts of n-6 PUFA, typically in the range of 8–
20%,[33,34] therefore olive oil was used as a control to assess the
effect of high n-6 PUFA.
The starch control (group 1) was used as the basic control,
since starch was added to all groups in varying amounts to ob-
tain isocaloric conditions in all cases. The starch used was native
potato starch (The Carl Roth GmbH+Co.KG, Germany), starch
+ FOS (group 4, FOS control) was used as a control for com-
parisons of groups where FOS was added to the sugars. FOS was
inulin-type (DP4-5, MW: 624–679 from chicory root with 95% pu-
rity, Boneo GmbH, Germany). Starch + olive (group 7) was used
as a control group to assess the effect of higher concentrations of
n-6 PUFA, which were added as part of the fat in the diet of all
other groups to trigger low-grade inflammation.
The rats were housed in a climate-controlled room (20–22 °C,
50 ± 10% relative humidity) with 12-h light/12-h dark cycle and
fed the starch diet (control) during a 2 week adaptation period.
The baseline control group was sacrificed at day 0. Six out of 12
animals per group were fed their respective diet for 6 weeks and
the other six animals were fed for 12 weeks. Water was available
ad libitum.
Energy intake and BW were recorded weekly. At the end of the
respective feeding period, the rats were fasted for 12 h, anes-
thetized with carbon dioxide gas, and killed by decapitation.
Blood was collected into heparinized monovettes (Monovette,
Sarstedt, Germany), and feces and intestinal contents into Ep-
pendorf tubes. Tissues (liver, kidney, brain, and small and large
intestines) were excised, placed in cryotubes, and snap-frozen
Mol. Nutr. Food Res. 2021, 65, 2001133 2001133 (2 of 10) © 2021 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH
www.advancedsciencenews.com www.mnf-journal.com
Table 1.Macronutrient and micronutrient composition of the seven experimental diets.
Starch (control) Fructose Galactose
Starch + FOS
(FOS Control) Fructose + FOS Galactose + FOS
Starch + olive
(negative control)
g kcal g kcal g kcal g kcal g kcal g kcal g kcal
Carbohydrate
Starch 61.5 62.0 11.5 11.6 11.5 11.6 54.0 56.5 4.0 4.2 4.0 4.2 61.5 62.0
Fructose - - 50.0 50.4 - - - - 50.0 52.4 - - - -
Galactose - - - - 50.0 50.4 - - - - 50.0 52.4 - -
FOS - - - - - - 15.0 7.9 15.0 7.9 15.0 7.9 - -
Cellulose 12.5 6.3 12.5 6.3 12.5 6.3 5.0 2.6 5.0 2.6 5.0 2.6 12.5 6.3
Protein 18.0 18.1 18.0 18.1 18.0 18.1 18.0 18.9 18.0 18.9 18.0 18.9 18.0 18.1
Fat
Safflower oil 6.0 13.6 6.0 13.6 6.0 13.6 6.0 14.1 6.0 14.1 6.0 14.1 - -
Olive oil - - - - - - - - - - - - 6.0 13.6
Minerals and vitamins 2.0 - 2.0 - 2.0 - 2.0 - 2.0 - 2.0 - 2.0 -
Total 100 g 100 kcal 100 g 100 kcal 100 g 100 kcal 100 g 100 kcal 100 g 100 kcal 100 g 100 kcal 100 g 100 kcal
FOS, fructooligosaccharides; kcal, kilocalorie.
in liquid nitrogen. Plasma and serum were separated from the
blood cells as soon as possible after collection. All samples were
immediately stored at −80 °C until further analysis.
After 2 weeks of the 12 week intervention, the dietary regime
for the galactose and galactose + FOS groups was modified in
response to adverse effects (polyuria and lens opacity) observed
in the rats in these two groups. The rats in these groups were
provided with the intervention diet for 4 days, followed by 3 days
on starch (control) diet, from week 3 through 12 of the study.
During the study, only one rat (from starch + FOS group) died,
due to volvulus.
2.2. Biochemical Analyses
Plasma AGEs, uric acid, creatinine, urea, alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), aspartate aminotrans-
ferase (AST), triglycerides, total cholesterol, high-density lipopro-
tein (HDL), low-density lipoprotein/very low-density lipoprotein
(LDL/VLDL), C-reactive protein (CRP), zonulin, endotoxin, and
serum insulin were measured.
Insulin (E-EL-R2466), CRP (E-EL-R0022), and creatinine (E-
EL-0058) were analyzed using commercial sandwich enzyme-
linked immunosorbent assays (ELISA) and urea (E-BC-K183).
ALT (E-BC-K235), ALP (E-BC-K092), AST (E-BC-K236), uric acid
(E-BC-K016), and triglycerides (E-BC-K238) were analyzed us-
ing a colorimetric method purchased from Elabscience Biotech-
nology Inc., UK. Cholesterol assay kits for assessment of HDL
and LDL/VLDL colorimetric assay kits (ab65390) were pur-
chased from Abcam plc., UK. Zonulin (MBS747447) and endo-
toxin (MBS2606662) were analyzed using ELISA (MyBiosource,
Inc., USA). All measurements were conducted according to the
manufacturer’s instructions. Homeostasis model assessment-
estimated insulin resistance (HOMA-IR) was calculated accord-
ing to the formula: fasting insulin (uIU dL−1) × fasting glucose
(mg dL−1)/405.[35]
AGEs in plasma were measured by ultra high-performance
liquid chromatography (UHPLC)-tandem mass spectrometry,[22]
and Nɛ-(carboxymethyl)lysine (CML), pentosidine, and lysine
were quantified. In brief, 50 µL of sample were hydrolyzed with
500 µL of 0.6 M trichloroacetic acid and 50 mL of 6 M hydrochlo-
ric acid for 2 h at 60 °C. The analyses were performed on a UH-
PLC coupled to a triple quadrupole mass spectrometer (AB-Sciex
Triple Quad 5500, Milan, Italy), equipped with a Turbo ion ESI
source. Analytes were separated on a reversed-phase C18 column
(Kinetex 100 × 2.1 mm, 1.7 µm particle size, Phenomenex) at
a flow rate of 0.35 µL min−1. A gradient mobile phase compo-
sition of 95/5–40/60 over 25 min in 5 nM heptafluorobutanoic
acid/acetonitrile was adopted. The liquid chromatograph column
eluent was delivered to the Turbo ion source using nitrogen as a
sheath (GS1) and curtain (CUR) gas, and air as reagent gas (GS2).
The source voltage was set at 4.5 kV in positive mode, CUR 26 ar-
bitrary units (arb), GS1 45 arb, and GS2 50 arb. The heated capil-
lary was maintained at 275 °C. The MRM transitions and param-
eters were as follows: Nɛ-(carboxymethyl)lysine (m/z) 205@84,
declustering potential (DP) 100 V, entrance potential (EP) 7 V, col-
lision energy (CE) 32 V; pentosidine (m/z) 379@316, DP 120 V,
EP 11 V, CE 33 V; and lysine (m/z) 147@84, DP 80 V, EP 8 V,
CE 21 V. Quantification of analytes was performed using CML,
pentosidine, and lysine analytical standard calibration curves at
concentrations of 10, 50, 100, 250, 300, and 500 µg L−1. Measured
concentration of analytes in samples was always within the linear
range of calibration. Coefficient of variation for the above analy-
ses ranged from 8% to 14%.
2.3. Statistical Analysis
Statistical analysis was carried out using SAS statistical analysis
software (release 9.4; SAS Institute, Cary, NC, USA). Changes in
BW over the 12 week study period were analyzed by repeated-
measures analysis of variance (ANOVA). Differences between
diets were evaluated by one-way ANOVA, followed by Tukey’s
multiple comparison test. Effect of diet after 12 weeks was
the primary outcome. If effects of specific diets were observed
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Figure 1. Effects of high-carbohydrate diets (fructose and galactose), with and without fructooligosaccharides (FOS), on A) body weight (g) and B)
energy intake (kcal) in rats during the 12 week study. Body weight and energy intake analyzed by repeated-measures. ANOVA with Tukey’s test was used
to compare differences between groups. Means with different superscripts (lowercase letters) are significantly different (p < 0.05).
after 12 weeks, a secondary analysis was conducted to evalu-
ate whether effects were evident already after 6 weeks. Assump-
tion of normality and homogeneity of variance were tested using
the Shapiro–Wilks test. Data not normally distributed were log-
transformed prior to analysis. Values of p < 0.05 were considered
significant. All results are presented as least square (LS) means
± standard error of the mean (SEM), adjusted for baseline values
obtained from the baseline group to nullify pre-existing differ-
ences.
3. Results
3.1. Effects of Diet on Energy Intake and BW
After 12 weeks of ad libitum isocaloric food intake, rats on the
galactose and galactose + FOS diets (groups 3 and 6) had signifi-
cantly lower BW than the other groups (Figure 1A). These differ-
ences became evident after 3 weeks of intervention. The galactose
and galactose+ FOS groups had lower energy intake at the begin-
ning of the experiment, but higher energy intake than the other
groups between 3 and 6 weeks (Figure 1B). Despite the higher
energy intake after 12 week intervention, the rats in the galactose
and galactose + FOS groups gained less weight than the other
groups. Moreover, higher energy intake was observed in the fruc-
tose than starch+ FOS (FOS control) and fructose+ FOS groups,
but no significant difference was observed in BW changes.
3.2. Effects on Blood Glucose and Insulin
No significant difference was found in blood glucose concentra-
tion between the groups after 12 weeks. Significantly higher in-
sulin concentration was observed in the galactose + FOS group
compared with the starch + FOS (FOS control) group after 12
weeks. Insulin concentration was also higher in the galactose +
FOS group compared with the starch (control), fructose + FOS,
and starch + FOS (FOS control) groups after 6 weeks (data not
shown). HOMA-IR concentration was significantly higher in the
fructose group than in all other groups except fructose + FOS
and galactose + FOS (Table 2).
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Table 2. Effects of high-carbohydrate diets (fructose and galactose), with and without additional fructooligosaccharides (FOS), on metabolic factors in








Fructose Fructose + FOS Galactose Galactose + FOS
Blood glucose [mg dL−1] 61.67 ± 5.70 54.17 ± 2.10 64.00 ± 7.13 73.50 ± 7.59 70.00 ± 7.39 55.00 ± 4.86 54.00 ± 3.52
Insulin [ng mL−1]
a) ) 6.33 ± 0.82ab 5.42 ± 0.57ab 4.50 ± 0.57b 6.62 ± 0.70ab 6.74 ± 0.79ab 6.14 ± 0.41ab 7.89 ± 0.35a
HOMA-IR [mg dL−1] 20.27 ± 0.98b 18.18 ± 2.23b 17.30 ± 2.33b 29.78 ± 4.02a 28.46 ± 3.86ab 20.8 ± 2.55b 25.87 ± 1.49ab
HOMA-IR, homeostasis model assessment-estimated insulin resistance.
a)
Measured in serum. Values shown are LS mean ± SEM of six rats. Groups were compared by
one-way ANOVA followed by Tukey’s test. LS mean with different superscripts (lowercase letters) differ significantly (p < 0.05).
Figure 2. Effects of high-carbohydrate diets (fructose and galactose), with and without fructooligosaccharides (FOS), on lipid profiles in rat plasma
after 12 weeks. A) Total cholesterol, B) triglycerides, C) high-density lipoprotein (HDL), and D) low-density lipoprotein/very low-density lipoprotein
(LDL/VLDL). Values shown are LS mean ± SEM of six rats. Groups were compared by one-way ANOVA followed by Tukey’s test. LS means with different
superscripts (lowercase letters) differ significantly (p < 0.05).
3.3. Effects on Lipid Profile
Plasma cholesterol concentrations were significantly higher in
the galactose and galactose + FOS groups than in the starch
+ FOS group after 12 weeks (Figure 2A). However, lower total
cholesterol concentration was observed in the galactose + FOS
and starch + olive (negative control) groups than in other groups
at 6 week (data not shown).
Plasma HDL concentration was significantly higher in the
galactose + FOS group compared with the starch + FOS (FOS
control) after 12 weeks (Figure 2C). Significantly higher HDL
concentration was also observed in the galactose and galactose
+ FOS groups than in all other groups except fructose group at
6 week (data not shown). Moreover, LDL/VLDL concentration
was significantly higher in the fructose + FOS and galactose
groups than in the starch+ FOS (FOS control) group (Figure 2D).
At 6 week, LDL/VLDL concentration was significantly higher in
the galactose group than in the other groups (data not shown). In
general, no clear pattern was observed for total cholesterol and
HDL concentration with addition of FOS to the diet. However,
a decreasing trend in LDL/VLDL concentration was seen in the
galactose+FOS group. No difference between diets was observed
for triglyceride concentration after 12 weeks (Figure 2B).
3.4. Effects on Inflammatory Biomarkers
No significant differences between the diets were found for any
of the inflammation biomarkers analyzed, i.e., CRP, TNF-𝛼, IL-6,
and IL-1𝛽, after 12 weeks (Figure 3).
3.5. Effects of Diet on AGEs—Inflammation-Related Markers
Plasma concentrations of CML were significantly higher in the
galactose and starch + olive (negative control) groups than in
the starch (control), starch + FOS (FOS control), and fructose
+ FOS groups after 12 weeks. Significantly higher pentosidine
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Figure 3. Effects of high-carbohydrate diets (fructose and galactose), with and without fructooligosaccharides (FOS), on pro-inflammatory biomarkers
in rat plasma after 12 weeks. A) C-reactive protein (CRP), B) tumor nuclear factor-alpha (TNF-𝛼), C) interleukin-6 (IL-6), and D) interleukin-1𝛽 (IL-1𝛽).
Values shown are LS mean ± SEM of six rats. Groups were compared by one-way ANOVA followed by Tukey’s test. LS means with different superscripts
(lowercase letters) differ significantly (p < 0.05).
concentration was found in the galactose group compared with
the starch (control), starch + FOS (FOS control), and fructose
+ FOS groups. Moreover, both CML and pentosidine concentra-
tions were significantly higher in the starch + FOS (FOS control)
group than in other groups at 6 week (data not shown). In gen-
eral, lower CML and pentosidine concentration were observed in
both the fructose and galactose groups after treatment with FOS
(Figure 4A,B).
Lysine concentration was significantly higher in the galactose
+FOSgroup comparedwith all other groups except starch+ olive
(negative control) and starch+ FOS (FOS control) (Figure 4C). At
6week, lysine concentrationwas significantly higher in the starch
+ olive (negative control) group than in all other groups except
starch + FOS (data not shown). Overall, lysine concentration in-
creased for the fructose and galactose diets with added FOS.
3.6. Effects on Intestinal Permeability Parameters
Significantly higher zonulin concentration was observed in the
galactose + FOS group compared with the fructose and starch
+ olive (negative control) groups after 12 weeks. Endotoxin con-
centration was significantly lower in the galactose group than in
the starch (control) and starch+ olive (control) groups (Figure 5).
At 6 week, zonulin concentration was significantly higher in the
galactose and galactose + FOS groups than in the starch (con-
trol), starch + FOS (FOS control), and fructose groups, whereas
endotoxin concentration was significantly lower in the galactose
+ FOS than fructose + FOS group (data not shown).
4. Discussion
This study investigated the effects of high intake of fructose and
galactose, with and without additional FOS, on metabolic fac-
tors and inflammatory and gut integrity markers in rats after a
12 week intervention. A high amount of the omega-6 linoleic
acid was added in all diets except starch + olive (negative con-
trol), to elicit low-grade inflammation.[36] Numerous studies have
investigated the effects of diets rich in simple carbohydrates on
metabolic factors and inflammation.[37] To our knowledge, this is
the first animal study to evaluate the impact of high-fructose and
high-galactose diets to which FOS had been added to mitigate
the adverse effects of these simple sugars. In general, the inter-
vention diets affected several metabolic factors and gut integrity
markers, but no significant changes in inflammatory markers
were found.
The results showed that a high-galactose diet (with or without
FOS) resulted in a smaller increase in BW between weeks 3 and
12 of intervention than the other diets tested. In addition, clinical
symptoms were manifested in rats in the galactose and galactose
+ FOS groups, with most rats in these two groups displaying
polyuria and lens opacity after 2 weeks of intervention. Similarly,
previous studies have shown that rats fed galactose doses corre-
sponding to 50% of total energy in the diet did not gain weight
normally.[38,39] The dose fed in those studies and in the present
study (50%E) might have been high enough to induce a toxic
effect of galactose,[40,41] which could have affected measurement
of metabolic markers in our intervention. Another study found
that intake of galactose at 12% of total energy for 3 weeks caused
lower BW in rats, which was alleviated when galactose was
reduced to 10% of total energy in the diet.[39] High intake of
galactose is reported to result in a significant proportion of the
galactose being excreted with the urine,[38,42] causing the rats
fed the galactose and galactose + FOS diets in the present study
to drink large amounts of water and to develop polyuria, due
to the osmotic effect of galactose.[38,39] It has been shown that a
high dose of galactose increases hepatic uridylation of galactose,
leading to hypergalactosemia and loss of galactose into the
urine.[43] The unmetabolized galactose is then converted into
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Figure 4. Effects of high-carbohydrate diets (fructose and galactose), with
and without fructooligosaccharides (FOS), on advanced glycation end
products (AGEs) in rats. A) Nɛ-(carboxymethyl)lysine (CML), B) pentosi-
dine, and C) lysine after 12 weeks. Values shown are LS mean± SEM of six
rats. Groups were compared by one-way ANOVA followed by Tukey’s test.
LS means with different superscripts (lowercase letters) differ significantly
(p < 0.05).
galactitol by aldose reductase, which causes cataracts in animal
models.[17,39,42]
Energy intake in the galactose and galactose+ FOS groups was
lower than in the other groups at the beginning of the interven-
tion.However, aftermodification of the feeding plan for these two
groups, the energy intake increased to reach a level similar to that
of the other groups after 5 weeks. This may reflect the adaptation
period of the galactose-fed rats to a new dietary regime.[38,44]
Adversemetabolic effects of high-sugar diets, particularly fruc-
tose and galactose, have been reported previously.[45,46] Both ani-
Figure 5. Effects of high-carbohydrate diets (fructose and galactose), with
andwithout fructooligosaccharides (FOS), on A) zonulin and B) endotoxin
in rat plasma after 12 weeks. Values shown are LS mean ± SEM of six
rats. Groups were compared by one-way ANOVA followed by Tukey’s test.
LS means with different superscripts (lowercase letters) differ significantly
differ (p < 0.05).
mal and human studies have shown that intake of fructose, com-
pared with glucose, sucrose, and lactose, has only minor effects
on blood glucose and insulin.[47] Similarly, little effect on fast-
ing blood glucose was observed in rats fed the fructose diet that
may be due to slow absorption rate and because fructose is first
converted to glucose in the liver.[47] Galactose also has little im-
pact on blood glucose due to hepaticmetabolism and interference
with glucose release from the liver, inducing hypoglycemia.[47,48]
However, high insulin concentration was observed in rats fed the
galactose + FOS diet and it could be explained by the incretin
effect, i.e., insulin secretion induced by glucagon-like peptide-
1 (GLP-1) and/or glucose-dependent insulinotrophic polypeptide
(GIP).[49] It has been shown that galactose stimulates GIP secre-
tion, and subsequently insulin secretion, in humans.[49,50] A diet
with additional FOS could also contribute to increased incretin
secretion, through gut fermentation.[51] Gut fermentation of FOS
leads to increased SCFA production, which has been shown to
enhance GLP-1 and GIP secretion by intestinal L-cells.[51] We
measured the HOMA-IR index to assess insulin resistance.
We expected the diets high in sugar to alter concentrations
of blood lipids, including total cholesterol, HDL, LDL/VLDL,
and triglycerides, as reported in previous studies.[52,53] For ex-
ample, it has been shown that a high-fructose diet may re-
sult in acute and chronic alteration of blood lipids,[54] and
that a diet containing higher fructose than glucose can cause
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lipid abnormalities, including increased total cholesterol, LDL,
and triglyceride concentrations.[52] D-galactose treated mice have
also been reported to demonstrate an increase in cholesterol
concentration.[55] In line with previous findings, we observed
higher total cholesterol concentration in rats fed the galactose
and galactose + FOS diets than the starch + FOS (FOS control)
diet. In other studies on both humans and animals, FOS has been
reported to reduce cholesterol concentration,[56] so the increase
we observed in total cholesterol concentration in the galactose +
FOS group after the 12 week intervention remains unexplained.
Many studies have reported decreases in HDL concentration af-
ter high fructose or high galactose intake.[52,55] In contrast, we
observed a similar response in HDL as in total cholesterol con-
centration after high intake of fructose and galactose, for under-
lying reasons that are still unclear. Our results are in agreement
with previous studies reporting unfavorable effects of high sugar
intake in increasing LDL cholesterol [57] after a few weeks of high
fructose and galactose intake.[57,58] Higher LDL/VLDL concentra-
tions were observed in rats fed the fructose + FOS and galactose
diets than the starch+ FOS (FOS control) diet. Overall, a decreas-
ing trend in LDL/VLDL concentration was observed in rats fed
the galactose+ FOS diet. Although numerous studies on rodents
report higher plasma triglycerides due to lipogenesis induced by
fructose intake,[54,59] our study did not support these findings.
Reduced triglyceride concentration after ingestion of FOS and
oligofructose due to inhibition of hepatic de novo fatty acid syn-
thesis [56] could explain the trend for a lowering in triglyceride
concentration observed after intake of FOS in this study.
The major AGEs from exogenous sources are methylglyoxal-
hydroimidazole (MG-H1), CML, carboxyethyl-lysine, pentosi-
dine, and pyrraline.[60] CML and pentosidine are commonly used
as biomarkers of glycation processes.[61] Numerous studies have
suggested that diets high in fructose and galactose increase AGE
accumulation in different tissues.[19,62] Direct comparison of dif-
ferent carbohydrate dietary regimens on systemic AGE concen-
trations was performed for the first time in the present study.
The results showed a tendency for higher concentrations of AGEs
in rats exposed to the galactose diet compared with the fruc-
tose diet, despite lower weekly exposure to simple sugar in the
galactose groups compared with the fructose groups. These find-
ings may suggest higher reactivity of galactose in terms of evok-
ing protein glycation compared with fructose in our experimen-
tal conditions. However, we cannot exclude the possibility that
the high AGE concentrations detected in the galactose groups
were a consequence of the toxic impact of galactose, which would
confirm the role of AGEs as early biomarkers of sugar-induced
changes in health status. We observed an increase in CML con-
centrations in the galactose and starch + olive (negative control)
groups compared with the starch (control), starch + FOS (FOS
control), fructose, and fructose + FOS groups, where systemic
CML concentrations reached their highest level after 12 weeks.
Pentosidine, a fluorescent lysine-arginine cross-linked AGE com-
pound derived from pentose, was present at higher concentra-
tions in plasma of the galactose group than in other groups in
this study. Accumulation of both CML and pentosidine has been
linked with pathological development such as chronic kidney dis-
ease and Alzheimer’s disease.[63,64] Although pentosidine is typi-
cally formed from a pentose, treatment with D-galactose in mice
for 8 weeks has demonstrated an accumulation of pentosidine
and CML in the brain.[65] Previous studies have suggested that
high fructose and glucose concentrations also play an important
role in facilitating the accumulation of pentosidine in the skin,
aortic tracheal, and tendon tail collagen in rodents.[66,67] Lysine
and arginine are major sites of glycation in many proteins, in-
cluding hemoglobin and albumin. Antiglycation activity is usu-
ally assessed through estimation of carbonyl content and free
lysine.[68] Significantly higher lysine concentration was found in
the galactose + FOS group in this study. Overall, the analysis of
AGE concentrations in groups of rats receiving different types of
carbohydrates demonstrated a lowering of CML and pentosidine
concentrations with added FOS.
The intestinal barrier plays a vital role in regulation of host
immune function and health.[69] Zonulin, a protein involved
in regulation of epithelial tight junctions in the small and
large intestine, has been proposed as a biomarker of intestinal
permeability.[70] Higher expression of zonulin has been found
in the early stage of disease.[71] Higher expression of endo-
toxin in the blood indicates epithelial barrier dysfunction and
promotes inflammatory processes.[72] Endotoxin, also known as
lipopolysaccharides (LPS), is a major component of the outer
membrane of Gram-negative bacteria. Fructose malabsorption
promotes gut permeability, and higher fructose intake promotes
gut inflammation and an accompanying rise in blood endotoxin
concentrations due to endothelial dysfunction and decline of
tight-junction proteins.[29,73] In this study, inconsistent changes
in zonulin concentrations were observed in response to endo-
toxin expression in the plasma.
One potential reason for lower expression of zonulin and en-
dotoxin after the 12 week intervention may be a protective effect
of intestinal alkaline phosphatase (IAP). Emerging studies on the
favorable effects of IAP in different organs in humans and ani-
mals have found that animal ALP consists of two classes: 1) tissue
non-specific ALP, expressed in liver, kidney, bone, and plasma
and 2) tissue-specific isozymes, including IAP, which play an im-
portant role in intestinal homeostasis and health through inter-
action with gut microbiota, diet, and gut.[74] In the intestine, IAP
detoxifies endotoxin and protects the host from bacterial inva-
sion by dephosphorylation of bacterial-derived LPS and is sug-
gested to be a potential intestinal microbiota regulator.[75] More-
over, IAP is expressed and secreted by intestinal epithelium and
remains biologically active in the intestinal lumen and mucosal
membrane.[74] We analyzed ALP concentrations in plasma, and
not in the intestine, and were therefore unable to confirm pre-
vious findings (Table S1, Supporting Information). However, it
has been reported that around 1–2% of IAP is secreted into the
blood circulation, which may widen its activity towards systemic
infections.[74] Dietary fermentable fiber, including FOS, galac-
tooligosaccharides, and raffinose, also increases colonic and in-
testinal activity.[76]
Our study has several limitations. First, the high dose of
fructose and galactose used may have caused a mild toxic effect
on the rats. Second, slight changes in the study design due to
clinical symptoms as demonstrated in the rats fed the galactose
and galactose + FOS diets made the interpretation of the results
more challenging. Third, the results from the present rat study
cannot be directly translated to humans. Nevertheless, this study
has also several strengths. First, the study was large and com-
pared the effects of different sugars with and without added fiber
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under isocaloric conditions. Second, three control groups were
included that allowed us to evaluate the effects of the sugars,
sugar with added FOS, and the impact of added n-6 to evoke
inflammation. Third, by using a rat model, we could control the
conditions to minimize the environmental conditions that may
otherwise have affected the results.
In summary, type of carbohydrate in the diet affects metabolic
effects in a complex way and the net effects are difficult to pre-
dict. The results in the present study indicated that high-galactose
and galactose + FOS diets have more severe adverse effects on
metabolic factors, lipid profiles, AGEs, and intestinal permeabil-
ity than high-fructose and fructose + FOS diets. However, the ef-
fects obtained for the galactose and galactose + FOS groups may
have been confounded by the clinical symptoms manifested in
these groups at the beginning of the intervention. We found no
clear benefits of added FOS in the diet as a strategy to mitigate
the adverse effects of high fructose and high galactose intake. Fur-
ther studies should seek to determine the threshold dietary dose
of galactose to avoid manifestation of clinical symptoms and the
optimal dose for FOS to obtain significant beneficial effects. Mea-
surement of IAP concentration could be included in future stud-
ies, as IAP plays an essential role in gut integrity, inflammation,
and microbiota composition.
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